XOMA (XOMA)
(Delayed Data from NSDQ)
$26.50 USD
+1.09 (4.29%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $25.98 -0.52 (-1.96%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 41 - 60 ( 328 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Expecting Strong Partner Data Catalysts and Continued Shopping in 2021; Target Increased to $56
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q3: NIS793 Triggers $25M Milestone; Multiple Value-Driving Catalysts in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Start a Study, Cash a Big Check; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials; Royalty Portfolio Coming into Focus in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
PacGrow Healthcare Conference: Day 1 - 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
1Q20 Results; Steady as She Goes Toward More Deals
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Active PoC Assets, Current Phase .2 Trials - Q4/FY19 Results
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2019 Results; Asset Base and Opportunities Continue to Grow
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Differentiated IL-2 Program Finds First Potential Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
XOMA Partnered Assets Featured Prominently During Novartis R-D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
3Q19 Results; Visibility Continues to Increase on Partnered Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Assets Continue to Grow in Numbers as New Business Model Is Validated Again; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Expanded Portfolio of Milestone and Royalty Bearing Assets
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2Q19 Results; Shopping Continues as Partners Advance Pipelines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J